Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Photogen financing under threat:

This article was originally published in Clinica

Executive Summary

Photogen Technologies of New Hope, Pennsylvania, has postponed a shareholder vote on a planned sale of shares to raise $16m after the investors indicated that they may not fully fund it under the current terms. The company is now negotiating a restructuring of the deal, which was to fund a reorganisation of the company around cardiovascular imaging and lymphographic cancer diagnosis following a spin-off of its photodynamic therapy and laser devices. Photogen has a business venture in cancer diagnosis with Elan, the troubled Irish speciality pharmaceuticals group whose joint venture and off-balance sheet accounting practices are under investigation, and which has decided to pull out of oncology.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts